Drug
Lomedeucitinib clinical trials
Also written BMS-986322.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How studies write it
Studies that test it under each name
Development codes
- BMS-986322
- 5
Studies by the year they started
5 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2022 | 3 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Janus Kinase Inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses lomedeucitinib is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe PsoriasisCompletedPhase 2Bristol-Myers SquibbNCT05730725Written as BMS-986322
- A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT06088264Written as BMS-986322
- A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05615012Written as BMS-986322
- A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05579574Written as BMS-986322
- A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentCompletedPhase 1Bristol-Myers SquibbNCT05546151Written as BMS-986322
Given in every arm · 1 — lomedeucitinib is usual care beside what is tested
Codes
What other systems call lomedeucitinib · ClinicalTrials.gg INT016492
- UNII (FDA) EYQ7KA55XALOMEDEUCITINIBOne source FDA
- NCI Thesaurus C203082LomedeucitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EYQ7KA55XA | LOMEDEUCITINIB | One source FDA |
| NCI Thesaurus | C203082 | Lomedeucitinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.